Cisplatin-induced hyponatremia

被引:0
|
作者
Peyrade, F
Taillan, B
Lebrun, C
Bendini, JC
Passerron, C
Dujardin, P
机构
[1] HOP CIMIEZ,SERV HEMATOL MED INTERNE,F-06003 NICE,FRANCE
[2] HOP LOUIS PASTEUR,GRP NEUROONCOL,F-06002 NICE,FRANCE
来源
PRESSE MEDICALE | 1997年 / 26卷 / 32期
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Cisplatin is one of the most widely used agents in cancer treatment. Cisplatin regimens can lead to a more or less pronounced hyponatremia in 4 to 10% of cases due to salt wasting with hypomagnesemia and normokaliemia. Functional and renal failure and orthostatic hypotension can be observed. CASE REPORT: A 54-year-old woman with brain metastases of a non-small-cell lung cancer was given a chemotherapy regimen containing cisplatin. Hyponatremia mia with confusion occurred after each cisplatin perfusion. The diagnosis retained was cisplatin-induced salt wasting. The patient was given salt prolonged supplementation and carboplatin was substituted for cisplatin in the chemotherapy regimen. DISCUSSION: Hyponatremia frequently occurs in cancer patients. Cisplatin-induced hyponatremia requires specific management Treatment is based on sodium intake which sometimes takes several months to replete stores. Carboplatin can be used instead of cisplatin in case of major hyponatremia. (C) 1997, Masson, Paris.
引用
收藏
页码:1523 / 1525
页数:3
相关论文
共 50 条
  • [31] Mechanisms of Cisplatin-Induced Ototoxicity and Otoprotection
    Sheth, Sandeep
    Mukherjea, Debashree
    Rybak, Leonard P.
    Ramkumar, Vickram
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2017, 11
  • [32] Prevention of cisplatin-induced nephrotoxicity by methimazole
    Osman, AM
    El-Sayed, EM
    El-Demerdash, E
    Al-Hyder, A
    El-Didi, M
    Attia, AS
    Hamada, FMA
    PHARMACOLOGICAL RESEARCH, 2000, 41 (01) : 115 - 121
  • [33] CISPLATIN-INDUCED HYPERMAGNESIURIA AND HYPERCALCIURIA IN RATS
    DIRKS, JH
    WONG, NLM
    MAVICHAK, V
    SUTTON, RAL
    MINERAL AND ELECTROLYTE METABOLISM, 1983, 9 (03) : 166 - 167
  • [34] Metabolomic study of cisplatin-induced nephrotoxicity
    Portilla, D.
    Li, S.
    Nagothu, K. K.
    Megyesi, J.
    Kaissling, B.
    Schnackenberg, L.
    Safirstein, R. L.
    Beger, R. D.
    KIDNEY INTERNATIONAL, 2006, 69 (12) : 2194 - 2204
  • [35] CISPLATIN-INDUCED NEUROTOXICITY WITH SEIZURES IN FROGS
    BLISARD, KS
    HARRINGTON, DA
    ANNALS OF NEUROLOGY, 1989, 26 (03) : 336 - 341
  • [36] Hyperlipidaemia in cisplatin-induced nephrotic rats
    Abdel-Gayoum, AA
    El-Jenjan, KB
    Ghwarsha, KA
    HUMAN & EXPERIMENTAL TOXICOLOGY, 1999, 18 (07): : 454 - 459
  • [37] STS for cisplatin-induced hearing loss
    Landman, Allison
    LANCET ONCOLOGY, 2017, 18 (11): : 1440 - 1440
  • [38] Mechanisms of cisplatin-induced ototoxicity and prevention
    Rybak, Leonard P.
    Whitworth, Craig A.
    Mukherjea, Debashree
    Rarakumar, Vickram
    HEARING RESEARCH, 2007, 226 (1-2) : 157 - 167
  • [39] Cisplatin-induced hypomagnesernia and cardiac dysrhythmia
    Bashir, Hamid
    Crom, Debbie
    Metzger, Monika
    Mulcahey, Jean
    Jones, Debbie
    Hudson, Melissa M.
    PEDIATRIC BLOOD & CANCER, 2007, 49 (06) : 867 - 869
  • [40] The effects of lycopene on cisplatin-induced ototoxicity
    Mahmut Özkırış
    Zeliha Kapusuz
    Seyhan Karaçavuş
    Levent Saydam
    European Archives of Oto-Rhino-Laryngology, 2013, 270 : 3027 - 3033